1. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
BRAIN TUMORS
Ependymoma PETEY 774- II A randomized, Phase II study of single agent Kellie Nazemi, MD
205 Erlotinib versus oral etoposide in patients with 503-494-0829
recurrent or refractory pediatric Ependymoma
(OSI ) Rae Acosta RN, CPON
503-418-4467
Recurrent Low-Grade RAD001 II A phase II study of RAD001 (Everolimus) for Kellie Nazemi, MD
Gliomas children with chemotherapy and/or Radiation 503-494-0829
(POETIC) refractory progressive or recurrent low grade
gliomas Rae Acosta RN, CPON
503-418-4467
High Grade Gliomas ACNS0621 II Cilengitide (EMD 12194) in recurrent or Kellie Nazemi, MD
progressive and refractory childhood high grade 503-494-0829
(COG) Glioma
Rae Acosta RN, CPON
503-418-4467
Childhood ACNS0821 II Temozolomide with Irinotecan versus Kellie Nazemi, MD
Medulloblastoma / CNS Temozolomide plus Bevacizumab for refractory/ 503-494-0829
PNET (COG) Recurrent Medulloblastoma/CNS PNET of child-
hood, a COG Phase II randomized trial Rae Acosta RN, CPON
503-418-4467
Newly diagnosed High ACNS0822 I/II A randomized Phase I/II study of Vorinostat Kellie Nazemi, MD
Grade Gliomas And local irradiation OR Temozolomide and 503-494-0829
(COG) Local irradiation OR Bevacizumab and local
Irradiation followed by maintenance Bevacizu- Rae Acosta RN, CPON
mab and Temozolomide in children with newly 503-418-4467
Diagnosed High grade gliomas.
Newly diagnosed diffuse ACNS0927 I/II A phase I/II study of Suberoylanilide Hydrox- Kellie Nazemi, MD
Intrinsic Pontine Glioma amic 503-494-0829
(DIPG) (COG) Acid (SAHA,Vorinostat) and local irradiation,
Followed by maintenance SAHA in children with Rae Acosta RN, CPON
Newly diagnosed DIPG 503-418-4467
2. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 2
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
Solid Tumors
Solid Tumors ADVL0813 I A Phase I study of IMC-A12 (anti-insulin-like Suman Malempati, MD
Growth factor-1 Receptor Monoclonal antibody)
(COG) in combination with CCI-779 (temsirolimus) in Rae Acosta RN, CPON
Pediatric patients with recurrent or refractory 503-418-4467
solid tumors
Solid Tumors ADVL0815 I A phase I study of Pazopanib as a single agent for Suman Malempati, MD
children with refractory solid tumors
(COG) Rae Acosta RN, CPON
503-418-4467
Solid Tumors or ADVL0816 I A phase I study of Obatoclax (Pan Anit- Suman Malempati, MD
Leukemia Apoptotic BCL-2 family small molecule inhibi-
(COG) tor), in combination with Vincristine/ Rae Acosta RN, CPON
Doxorubicin/ Dexrazoxane, in children with 503-418-4467
Relapsed/Refractory solid tumors or Leukemia
Solid Tumors ADVL0821 II A phase II study of IMC-A12 in children with Suman Malempati, MD
Relapsed or refractory solid tumors
(COG) Rae Acosta RN, CPON
503-418-4467
Solid Tumors and ALCL ADVL0912 I/II PF-02341066 for ALK and C-Met for patients Suman Malempati, MD
with relapsed or refractory solid tumors and
(COG) ALCL Rae Acosta RN, CPON
503-418-4467
Recurrent or Refractory ADVL1013 I A Phase I study of MK-2206, an AKT inhibitor Suman Malempati, MD
Solid Tumors or In Pediatric patients with recurrent or refractory
Leukemia (COG) Solid tumors or Leukemia Rae Acosta RN, CPON
503-418-4467
3. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 3
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
Solid Tumors
Solid Tumors ADVL1011 I A phase I study of JAK Inhibition in children Suman Malempati, MD
With Relapsed or Refractory Solid Tumors,
(COG) Rae Acosta RN, CPON
503-418-4467
Solid Tumors ADVL0918 I A phase I study of of Temsirolimus in combina- Suman Malempati, MD
tion with Irinotecan and Temozolomide in
(COG) children , adolescents and young adults with Rae Acosta RN, CPON
relapsed or refractory solid tumors 503-418-4467
Solid Tumors AMG954- I Suman Malempati, MD
20050252 Panitumumab in children with solid tumors
Rae Acosta RN, CPON
(Amgen) 503-418-4467
Solid Tumors ADVL0413 I A phase I study of the Raf Kinase and Receptor Suman Malempati, MD
Tyrosine Kinase Inhibitor Sorafenib in children
(COG) With refractory solid tumors or refractory Rae Acosta RN, CPON
Leukemia's 503-418-4467
Solid Tumors ADVL0612 I A phase I study of Sunitinib and oral multi- Suman Malempati, MD
targeted tyrosine kinase inhibitor, in children with
(COG) refractory solid tumors Rae Acosta RN, CPON
503-418-4467
4. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 4
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
LEUKEMIA STUDIES
Philadelphia AALL0622 II Intensified Tyrosine Kinase Inhibitor Therapy Bill Chang, MD
Chromosome + ALL (Dasatinib) in Philadelphia Chromosome + ALL
(COG) Rae Acosta RN, CPON
503-418-4467
Relapsed KITE 2046 I/II Bendamustine (Treanda) in relapsed pediatric Bill Chang, MD
Acute Leukemia ALL
(Cephalon, Inc) Rae Acosta RN, CPON
503-418-4467
Pediatric AML E7373-G000- Pilot Pre-Induction Decitabine Priming for Pediatric Linda Stork, MD
202 AML subjects
Rae Acosta RN, CPON
(Eisai, Inc) 503-418-4467
Leukemia's and ADVL1011 I A phase I study of JAK Inhibition in children Suman Malempati, MD
Myeloproliferative With Relapsed or Refractory Solid Tumors,
Neoplasm's, (COG) Rae Acosta RN, CPON
Solid Tumors 503-418-4467
Ph+ Leukemia CA180226 II Dasatinib in Children and Adolescents with Ph+ Linda Stork, MD
Leukemia with resistance or Intolerance to
(BMS) Imatinib Rae Acosta RN, CPON
503-418-4467
Recurrent or Refractory ADVL1013 I A Phase I study of MK-2206, an AKT inhibitor Suman Malempati, MD
Solid Tumors or In Pediatric patients with recurrent or refractory
Leukemia (COG) Solid tumors or Leukemia Rae Acosta RN, CPON
503-418-4467
5. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 5
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
LEUKEMIA STUDIES
Solid Tumors or ADVL0816 I A phase I study of Obatoclax (Pan Anit- Suman Malempati, MD
Leukemia Apoptotic BCL-2 family small molecule inhibi-
(COG) tor), in combination with Vincristine/ Rae Acosta RN, CPON
Doxorubicin/ Dexrazoxane, in children with 503-418-4467
Relapsed/Refractory solid tumors or Leukemia
Solid Tumors or ADVL0413 I A phase I study of the Raf Kinase and Receptor Suman Malempati, MD
Refractory Leukemia Tyrosine Kinase Inhibitor Sorafenib in children
(COG) With refractory solid tumors or refractory Rae Acosta RN, CPON
(AML and FLT3-ITD Leukemia's 503-418-4467
mutation)
CD-22 + Leukemia ADVL04P2 I/II A phase I/II pilot study of Chemoimmunotherapy Suman Malempati, MD
With Epratuzumab for children with Relapsed
(COG) CD-22 + ALL Rae Acosta RN, CPON
503-418-4467
Rhabdomyosarcoma Studies
High Risk ARST08P1 Pilot A pilot study to evaluate novel agents Suman Malempati, MD
Rhabdomyocarcoma (Temozolomide and Cixutumumab) in
(COG) combination with intensive multi-agent interval Rae Acosta RN, CPON
Compressed therapy for patients with high risk 503-418-4467
Rhabdomyosarcoma
Rhabdomyosarcoma ARST0921 II A randomized Phase II trial of Bevacizumab Suman Malempati, MD
(Avastin) and Temsirolimus (Torisol) in
(COG) Combination with IV Vinorelbine and Rae Acosta RN, CPON
Cyclophosphamide in subjects with recurrent or 503-418-4467
Refractory Rhabdomyosarcoma
6. Pediatric Echocardiogram Lab Expansion
A Summary for Norman and Susan Hand
Page 6
Doernbecher Pediatric Oncology Phase I & II trials
Treatment Group ID Number Phase Study Name Site Investigator and
coordinator
Bonemarrow and stem cell transplant protocols
Severe aplastic anemia BMT CTN I/II Fludarabine-based conditioning for allogeneic Gabrielle Meyers, MD
0301 marrow transplantation from HLA compatible 503-494-1551
unrelated donors in severe aplastic anemia
(BMT CTN) Allison Moore RN
503-418-5341
Hodgkins disease and BUMELTT II A phase II study to evaluate the safety and Richard Maziarz, MD
non-hodgkins lymphoma efficacy of IV busulfan, melphalan, and thiotepa 503-494-1551
(OHSU) (BuMelTT) regimen followed by autologous
PBSC infusion for patients with hodgkins disease Allison Moore RN
and non-hodgkins lymphoma 503-418-5341l
Hematologic BU/FLU/TBI I/II A Phase I/Il non-myeloablative allogenic Richard Maziarz, MD
malignancies Hematopoietic stem cell transplant for the 503-494-1551
(OHSU) Treatment of patients with hematologic malig-
nancies using busulfan, fludarbine and total body Allison Moore RN
irradiation 503-418-5341
Hematologic T2008-005 I Phase I feasibility study of clofarabine and low Eneida Nemecek, MD
malignancies dose total body irradiation (TBI) as a non- 503-494-0829
(TACL) Myeloblative preperative regimen for stem cell
Multicenter transplant (SCT) for hematologic malignancies Allison Moore RN
503-418-5341
Ph+ Leukemia FHCRC 2223 I/II A multicenter phase I/II study of the prophylactic Michael Mauro, MD
inhibition of BCR-ABL tyrosine kinase by 503-494-1551
(FHCRC) Tasigna (Nilotinib) after HSCT for Ph+ leukemia
Allison Moore RN
503-418-5341
Interstitial pneumonia ASCT0521 II Soluble tumor necrosis factor: Enbrel Bill Chang, MD
Syndrome following (Etanercept) for the treatment of acute non- 503-494-0829
Allogeneic stem cell (COG) infectious pulmonary dysfunction (interstitial
transplant pneumonia syndrome) following allogeneic stem Allison Moore RN
cell transplantation. 503-418-5341